Stride News

Stride Analyst Ratings

BenzingaApr 25 12:34 ET

Stride Analyst Ratings

BenzingaApr 24 09:47 ET

Morgan Stanley Raises Price Target on Stride to $70 From $65, Cites 'Solid Quarter,' Keeps Equalweight Rating

MT NewswiresApr 24 07:16 ET

Stride Analyst Ratings

BenzingaApr 17 09:56 ET

Buy Rating Justified for Stride Inc. on Strong Market Position and Growth Prospects in Virtual Education

TipRanksMar 28 07:06 ET

Stride Analyst Ratings

BenzingaJan 29 16:06 ET

Stride Analyst Ratings

BenzingaJan 25 09:56 ET

Stride (LRN) Outpaces Expectations: A Comprehensive Buy Rating Justification

TipRanksJan 25 07:38 ET

Stride Analyst Ratings

BenzingaJan 24 11:05 ET

Stride, Inc. Outperforms With Strong Financial Results and Undervalued Stock: A Buy Rating Reaffirmed

TipRanksJan 24 09:45 ET

Hold Rating and Lowered Price Target for Reneo Pharmaceuticals Following STRIDE Study Setback and Operational Challenges

TipRanksDec 15, 2023 04:46 ET

What 6 Analyst Ratings Have To Say About Stride

BenzingaDec 4, 2023 13:00 ET

Stride Analyst Ratings

BenzingaDec 4, 2023 12:47 ET

BMO Capital Adjusts Stride's Price Target to $67 From $57, Maintains Outperform Rating

MT NewswiresNov 16, 2023 11:32 ET

The Latest Analyst Ratings for Stride

BenzingaNov 16, 2023 09:00 ET

Morgan Stanley Maintains Equal-Weight on Stride, Raises Price Target to $60

BenzingaNov 16, 2023 08:02 ET

Stride Analyst Ratings

BenzingaNov 16, 2023 08:01 ET

BMO Capital Maintains Outperform on Stride, Raises Price Target to $57

BenzingaOct 26, 2023 10:28 ET

Stride Analyst Ratings

BenzingaOct 26, 2023 10:27 ET

Stride's Positive Financial Performance and Growth Prospects Lead to Buy Rating

TipRanksOct 26, 2023 07:53 ET